NO994103L - Reverse hydroksamatderivater som metallproteaseinhibitorer - Google Patents
Reverse hydroksamatderivater som metallproteaseinhibitorerInfo
- Publication number
- NO994103L NO994103L NO994103A NO994103A NO994103L NO 994103 L NO994103 L NO 994103L NO 994103 A NO994103 A NO 994103A NO 994103 A NO994103 A NO 994103A NO 994103 L NO994103 L NO 994103L
- Authority
- NO
- Norway
- Prior art keywords
- ethyl
- hydrogen
- tnf
- protease inhibitors
- sec
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Detergent Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3911297P | 1997-02-26 | 1997-02-26 | |
| PCT/EP1998/001015 WO1998038179A1 (en) | 1997-02-26 | 1998-02-24 | Reverse hydroxamate derivatives as metalloprotease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO994103D0 NO994103D0 (no) | 1999-08-25 |
| NO994103L true NO994103L (no) | 1999-10-25 |
Family
ID=21903750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO994103A NO994103L (no) | 1997-02-26 | 1999-08-25 | Reverse hydroksamatderivater som metallproteaseinhibitorer |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1019386A1 (ja) |
| JP (1) | JP2001513767A (ja) |
| KR (1) | KR20000075681A (ja) |
| AP (1) | AP9901631A0 (ja) |
| AR (1) | AR013070A1 (ja) |
| AU (1) | AU6822398A (ja) |
| BR (1) | BR9807763A (ja) |
| CA (1) | CA2281664A1 (ja) |
| HR (1) | HRP980096A2 (ja) |
| IS (1) | IS5159A (ja) |
| NO (1) | NO994103L (ja) |
| PE (1) | PE59199A1 (ja) |
| PL (1) | PL335378A1 (ja) |
| TR (1) | TR199902063T2 (ja) |
| WO (1) | WO1998038179A1 (ja) |
| ZA (1) | ZA981532B (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
| PL194240B1 (pl) | 1998-02-07 | 2007-05-31 | British Biotech Pharm | Zastosowanie pochodnych N-formylohydroksyloaminy i amidowa pochodna N-formylohydroksyloaminy |
| GB9818621D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therapeutic agents |
| EP1121118A4 (en) * | 1998-08-26 | 2002-09-11 | Glaxo Group Ltd | FORMAMIDE-BASED THERAPEUTIC AGENTS |
| AU5688999A (en) * | 1998-08-26 | 2000-03-21 | Glaxo Group Limited | Formamide compounds as therapeutic agents |
| US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
| US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
| GB9918869D0 (en) * | 1999-08-10 | 1999-10-13 | British Biotech Pharm | Antibacterial agents |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| EP2319518A1 (en) | 2002-02-04 | 2011-05-11 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| CA2515534A1 (en) * | 2003-02-11 | 2004-08-26 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| EP1993583A4 (en) * | 2006-02-09 | 2010-06-23 | Burnham Inst | INHIBITORS OF MEMBRANE TYPE 1 TYPE MATRIX METALLOPROTEINASE FOR THE TREATMENT OF SUGAR DIABETES DEPENDING ON INSULIN |
| JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ，インク． | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
| CA2719745C (en) | 2008-03-25 | 2016-07-05 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| ATE541832T1 (de) | 2009-04-14 | 2012-02-15 | Affectis Pharmaceuticals Ag | Neuartige p2x7r-antagonisten und ihre verwendung |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| PT2699242T (pt) | 2011-04-19 | 2018-01-22 | Alfama Inc | Moléculas de libertação de monóxido de carbono e utilizações das mesmas |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2013013179A1 (en) | 2011-07-21 | 2013-01-24 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
| BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
| US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
| EP0740652B1 (en) * | 1994-01-20 | 1998-05-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
| HUP9903863A3 (en) * | 1995-11-23 | 2000-11-28 | British Biotech Pharm | Metalloproteinase inhibitors |
-
1998
- 1998-02-24 ZA ZA9801532A patent/ZA981532B/xx unknown
- 1998-02-24 WO PCT/EP1998/001015 patent/WO1998038179A1/en not_active Application Discontinuation
- 1998-02-24 PL PL98335378A patent/PL335378A1/xx unknown
- 1998-02-24 AU AU68223/98A patent/AU6822398A/en not_active Abandoned
- 1998-02-24 JP JP53728498A patent/JP2001513767A/ja active Pending
- 1998-02-24 HR HR60/039,112A patent/HRP980096A2/hr not_active Application Discontinuation
- 1998-02-24 CA CA002281664A patent/CA2281664A1/en not_active Abandoned
- 1998-02-24 BR BR9807763-5A patent/BR9807763A/pt not_active Application Discontinuation
- 1998-02-24 KR KR1019997007747A patent/KR20000075681A/ko not_active Application Discontinuation
- 1998-02-24 AP APAP/P/1999/001631A patent/AP9901631A0/en unknown
- 1998-02-24 EP EP98913575A patent/EP1019386A1/en not_active Withdrawn
- 1998-02-24 TR TR1999/02063T patent/TR199902063T2/xx unknown
- 1998-02-25 PE PE1998000138A patent/PE59199A1/es not_active Application Discontinuation
- 1998-02-25 AR ARP980100842A patent/AR013070A1/es unknown
-
1999
- 1999-08-20 IS IS5159A patent/IS5159A/is unknown
- 1999-08-25 NO NO994103A patent/NO994103L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO994103D0 (no) | 1999-08-25 |
| KR20000075681A (ko) | 2000-12-26 |
| PL335378A1 (en) | 2000-04-25 |
| EP1019386A1 (en) | 2000-07-19 |
| AR013070A1 (es) | 2000-12-13 |
| PE59199A1 (es) | 1999-06-24 |
| WO1998038179A1 (en) | 1998-09-03 |
| ZA981532B (en) | 1999-08-24 |
| CA2281664A1 (en) | 1998-09-03 |
| TR199902063T2 (xx) | 1999-12-21 |
| JP2001513767A (ja) | 2001-09-04 |
| IS5159A (is) | 1999-08-20 |
| HRP980096A2 (en) | 1998-12-31 |
| AU6822398A (en) | 1998-09-18 |
| BR9807763A (pt) | 2000-02-22 |
| AP9901631A0 (en) | 1999-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO994103L (no) | Reverse hydroksamatderivater som metallproteaseinhibitorer | |
| MY107740A (en) | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof | |
| MY136141A (en) | Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors | |
| NO20051788L (no) | Hydantoinderivater og deres anvendelse som TACE-inhibitorer | |
| TR200100472T2 (tr) | Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler | |
| CY2394B1 (en) | Use of sulphamate derivatives as steroid sulphatase inhibitors. | |
| DK1052984T3 (da) | Antibakterielle midler | |
| CA2396738A1 (en) | Thiazole derivatives as active superoxide radical inhibitors | |
| CA2055670A1 (en) | Retroviral protease inhibiting compounds | |
| WO2004014913A3 (en) | Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors | |
| EP0739338A4 (en) | NEW STERIN PROTEASE INHIBITORS: ISOTHIAZOLIDIN-3-ON-1,1-DIOXIDE AND 3-OXO-1,2,5-THIADIAZOLIDIN 1,1-DIOXIDE | |
| DK0810208T3 (da) | N-substituerede hydroxyethylamino sulfaminsyrederivater til anvendelse som inhibitorer af retrovirale proteaser | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| TR199802536T2 (xx) | Yeni amino asit t�revleri,trombin inhibit�rleri olarak kullan�lmalar�. | |
| MX9800718A (es) | Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida. | |
| NO934628L (no) | Retrovirus-protease-inhibitorer | |
| GB8622330D0 (en) | 4-substituted 6-alkylidenandrostene-3,17-dione derivatives | |
| HUP0101899A2 (hu) | Cisztein-aktivitástól függő enzimeket gátló hatású tiadiazolvegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MA27143A1 (fr) | Utilisation de derives de 2-amino-4- pyridylmethyl-thiazoline comme inhibiteurs de no-synthase inductible | |
| NO983444L (no) | Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer | |
| CA2214386A1 (en) | Optically active thiazolidinone derivatives | |
| WO2001056353A3 (fr) | Nouveau procede de synthese de esters de la n-[(s)-1-carboxybutyl]-(s)-alanine et application a la synthese du perindopril | |
| MXPA05000517A (es) | Derivados de sulfonilpiperidina que contienen una porcion alquenilo o alquinilo para uso como inhibidores de metaloproteinasas de matriz. | |
| DE69405760T2 (de) | 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren | |
| YU78001A (sh) | Derivati 6-(((aril i heteroaril)oksi)metil) naftalen-2- karboksimidamida, njihovo dobijanje i terapeutska primena |